Esophageal Cancer Pipeline Report, 2024 Updates: Analysis of Clinical Trials, Companies, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight

Esophageal Cancer Companies: Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical, Shanghai Henlius Biotech, Ipsen, Seagen, Bayer, Eli Lilly, Novartis, GlaxoSmithKline, Janssen Pharmaceutical, CStone Pharmaceuticals, Jacobio Pharmaceuticals, AstraZeneca, Sanofi, Genentech, Sinocelltech, Exelixis, BeiGene, Incyte Corporation, Merck, Symphogen, Adlai Nortye Biopharma, Hangzhou Neoantigen Therapeutics, Leap Therapeutics, Inc., MacroGenics, Bristol-Myers Squibb, and others.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 80+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Esophageal Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Esophageal Cancer Pipeline Insight [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

* Esophageal Cancer Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.
* Esophageal Cancer companies working in the treatment market are Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Henlius Biotech, Ipsen, Seagen Inc., Bayer, Eli Lilly and Company, Novartis Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical, CStone Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., AstraZeneca, Sanofi, Genentech, Sinocelltech Ltd., Exelixis, BeiGene, Sichuan Baili Pharmaceutical, Rapa Therapeutics LLC, Incyte Corporation, Merck KGaA, Symphogen, Adlai Nortye Biopharma Co., Ltd., Hangzhou Neoantigen Therapeutics, Leap Therapeutics, Inc., MacroGenics, Bristol-Myers Squibb, Integral Molecular, Keythera Pharmaceuticals (Australia) Pty Ltd, AP Biosciences., Athenex, Inc., Curis, Inc., Shenzhen Hornetcorn Bio-technology Company, LTD, Sunshine Lake Pharma Co., Ltd., Atreca, Inc., Pfizer, CARTEXELL, EMD Serono, and others, are developing therapies for the Esophageal Cancer treatment
* Emerging Esophageal Cancer therapies in the different phases of clinical trials are Durvalumab, Camrelizumab, Sym021, LGK974, Regorafenib, Serplulimab, Abemaciclib, THOR-707, Sym023, Anlotinib Hydrochloride, Ramucirumab, ATRC-101, Letetresgene Autoleucel, Larotinib, SCT-I10A, Cabozantinib, JAB-3068, Onivyde, SCT200, JAB-3312, DKN-01, TNO155, AP 203, S095033, SI B001, SCT-I10A, Apatinib, HR 070803, RAPA-201, Oraxol, M1231, iNeo Vac P01, QEQ278, Sunitinib malate, APX005M, DC-CIK, Amivantamab, CA-4948, Margetuximab, Tiragolumab, and Temozolomide, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.
* In September 2022, Daiichi Sankyo and Sarah Cannon Research Institute (SCRI) reported that extended follow-up data from a phase I/II trial of DS-7300 demonstrated sustained and promising tumor response in patients with various heavily treated cancers, such as lung, prostate, and esophageal cancer. The trial showed a response rate of 32%, with 38 patients experiencing positive responses among a total of 118 patients with different solid tumors. The study included small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), and endometrial cancer. DS-7300 doses ranged from 4.8 mg/kg to 16.0 mg/kg.
* Additionally, in September 2022, Integral Molecular granted a license to CARTEXELL, enabling them to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) monoclonal antibodies (MAbs). The agreement provided CARTEXELL with an exclusive worldwide license to utilize Integral Molecular's panel of fully humanized, high-affinity, and high-specificity CLDN18.2 MAbs for the development of CAR-T cell therapies targeting solid tumors like gastric, lung, pancreatic, and esophageal cancers. CARTEXELL will assume sole responsibility for all research, development, and commercial activities associated with the licensed antibodies.

Esophageal Cancer Overview

Esophageal cancer is a malignancy that develops in the esophagus, the muscular tube connecting the throat to the stomach. It is divided into two main types: squamous cell carcinoma and adenocarcinoma. Esophageal cancer is often diagnosed at an advanced stage, as early symptoms may be subtle or absent. Risk factors include tobacco and alcohol use, obesity, gastroesophageal reflux disease (GERD), and certain dietary factors. Common symptoms include difficulty swallowing, weight loss, chest pain, and persistent cough. Treatment options include surgery, chemotherapy, radiation therapy, and targeted therapy. Early detection and comprehensive treatment strategies are crucial in improving outcomes for individuals with esophageal cancer.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

* AN-0025: Adlai Nortye
* Tucatinib: Seagen
* APX 005M: Apexigen
* And Many Others

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Esophageal Cancer Molecule Type

Products have been categorized under various Molecule types, such as

* Oligonucleotide
* Peptide
* Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

* Esophageal Cancer Assessment by Product Type
* Esophageal Cancer By Stage and Product Type
* Esophageal Cancer Assessment by Route of Administration
* Esophageal Cancer By Stage and Route of Administration
* Esophageal Cancer Assessment by Molecule Type
* Esophageal Cancer by Stage and Molecule Type

DelveInsight's Esophageal Cancer Report covers around 80+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies @ @ Esophageal Cancer Clinical Trials advancements [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Esophageal Cancer companies developing therapies are Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Henlius Biotech, Ipsen, Seagen Inc., Bayer, Eli Lilly and Company, Novartis Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical, CStone Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., AstraZeneca, Sanofi, Genentech, Sinocelltech Ltd., Exelixis, BeiGene, Sichuan Baili Pharmaceutical, Rapa Therapeutics LLC, Incyte Corporation, Merck KGaA, Symphogen, Adlai Nortye Biopharma Co., Ltd., Hangzhou Neoantigen Therapeutics, Leap Therapeutics, Inc., MacroGenics, Bristol-Myers Squibb, Integral Molecular, Keythera Pharmaceuticals (Australia) Pty Ltd, AP Biosciences., Athenex, Inc., Curis, Inc., Shenzhen Hornetcorn Bio-technology Company, LTD, Sunshine Lake Pharma Co., Ltd., Atreca, Inc., Pfizer, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
* Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies @ https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Esophageal Cancer Pipeline Market Drivers

The esophageal cancer pipeline market is driven by several factors. Firstly, the increasing incidence and prevalence of esophageal cancer globally contribute to the growing demand for effective therapies, thereby driving the development of new drugs in the pipeline. Secondly, advancements in understanding the molecular mechanisms and genetic mutations associated with esophageal cancer have paved the way for targeted therapies, personalized medicine, and precision oncology approaches, driving research and development efforts. Additionally, the unmet medical needs in terms of improved survival rates, reduced treatment toxicity, and enhanced quality of life for esophageal cancer patients create opportunities for innovative therapeutic interventions. The potential for market growth and the urgency to address the significant healthcare burden associated with esophageal cancer also contribute to the driving forces in the pipeline market.

Esophageal Cancer Pipeline Market Barriers

The esophageal cancer pipeline market faces several barriers that impact the development and commercialization of new therapies. One major barrier is the complex nature of esophageal cancer, which exhibits heterogeneity in its histological subtypes, genetic mutations, and tumor microenvironment, making it challenging to identify effective treatment targets and develop targeted therapies. Additionally, the limited understanding of the underlying biology and molecular pathways involved in esophageal cancer poses challenges in drug discovery and development. Regulatory hurdles, high costs associated with clinical trials, and the need for extensive safety and efficacy data also present barriers to market entry. Moreover, the competitive landscape and the need for differentiation from existing treatment options further add to the challenges faced by pipeline products in the esophageal cancer market.

Scope of Esophageal Cancer Pipeline Drug Insight

* Coverage: Global
* Key Esophageal Cancer Companies: Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Henlius Biotech, Ipsen, Seagen Inc., Bayer, Eli Lilly and Company, Novartis Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutical, CStone Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., AstraZeneca, Sanofi, Genentech, Sinocelltech Ltd., Exelixis, BeiGene, Sichuan Baili Pharmaceutical, Rapa Therapeutics LLC, Incyte Corporation, Merck KGaA, Symphogen, Adlai Nortye Biopharma Co., Ltd., Hangzhou Neoantigen Therapeutics, Leap Therapeutics, Inc., MacroGenics, Bristol-Myers Squibb, Integral Molecular, Keythera Pharmaceuticals (Australia) Pty Ltd, AP Biosciences., Athenex, Inc., Curis, Inc., Shenzhen Hornetcorn Bio-technology Company, LTD, Sunshine Lake Pharma Co., Ltd., Atreca, Inc., Pfizer, CARTEXELL, EMD Serono, and others.
* Key Esophageal Cancer Therapies: Durvalumab, Camrelizumab, Sym021, LGK974, Regorafenib, Serplulimab, Abemaciclib, THOR-707, Sym023, Anlotinib Hydrochloride, Ramucirumab, ATRC-101, Letetresgene Autoleucel, Larotinib, SCT-I10A, Cabozantinib, JAB-3068, Onivyde, SCT200, JAB-3312, DKN-01, TNO155, AP 203, S095033, SI B001, SCT-I10A, Apatinib, HR 070803, RAPA-201, Oraxol, M1231, iNeo Vac P01, QEQ278, Sunitinib malate, APX005M, DC-CIK, Amivantamab, CA-4948, Margetuximab, Tiragolumab, and Temozolomide, and others.
* Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
* Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-pipeline-report-2024-updates-analysis-of-clinical-trials-companies-therapies-mechanism-of-action-route-of-administration-and-developments-by-delveinsight]
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services



This release was published on openPR.